• News
  • SAN DIEGO
  • Health

Sorrento Therapeutics granted funds for molecule inhibitor development

Sorrento Therapeutics Inc. (Nasdaq: SRNE), a late-stage clinical oncology company developing treatments for cancer, has received non-dilutive funding for the preclinical development of a small molecule inhibitor targeting the oncogenic transcription factor Myc.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Sorrento Therapeutics Inc.

Company Website

6042 Cornerstone Ct. West Ste., B
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
SRNE
4.01
  -0.16  
- 3.84%
355,969,000
16.40
3.10

Sorrento Therapeutics Inc. Executive(s):

Henry Ji

  • Chief Executive Officer

Richard Vincent

  • Chief Financial Officer

Similar Companies

NAICS - 541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
SIC - 3728 - AIRCRAFT PARTS AND AUXILIARY EQUIPMENT, NOT ELSEWHERE CLASSIFIED
SIC - 3769 - GUIDED MISSILE AND SPACE VEHICLE PARTS AND AUXILIARY EQUIPMENT, N
SIC - 3721 - AIRCRAFT
SIC - 3761 - GUIDED MISSILES AND SPACE VEHICLES
SIC - 3724 - AIRCRAFT ENGINES AND ENGINE PARTS
Subscribe Today!